Towards patient-specific management of trauma hemorrhage: the effect of resuscitation therapy on parameters of thromboelastometry.
Adult
Antifibrinolytic Agents
/ administration & dosage
Clinical Decision-Making
Decision Support Techniques
Erythrocyte Transfusion
/ adverse effects
Europe
Female
Fibrinogen
/ administration & dosage
Hemorrhage
/ blood
Hemostasis
/ drug effects
Humans
Male
Middle Aged
Patient Selection
Patient-Centered Care
Platelet Transfusion
/ adverse effects
Predictive Value of Tests
Prospective Studies
Resuscitation
/ adverse effects
Thrombelastography
Time Factors
Tranexamic Acid
/ administration & dosage
Treatment Outcome
Wounds and Injuries
/ blood
ROTEM
hemorrhage
transfusion
trauma
viscoelastic hemostatic assay
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
16
10
2018
pubmed:
5
1
2019
medline:
9
4
2020
entrez:
5
1
2019
Statut:
ppublish
Résumé
Essentials The response of thromboelastometry (ROTEM) parameters to therapy is unknown. We prospectively recruited hemorrhaging trauma patients in six level-1 trauma centres in Europe. Blood products and pro-coagulants prevent further derangement of ROTEM results. ROTEM algorithms can be used to treat and monitor trauma induced coagulopathy. SUMMARY: Background Rotational thromboelastometry (ROTEM) can detect trauma-induced coagulopathy (TIC) and is used in transfusion algorithms. The response of ROTEM to transfusion therapy is unknown. Objectives To determine the response of ROTEM profiles to therapy in bleeding trauma patients. Patients/Methods A prospective multicenter study in bleeding trauma patients (receiving ≥ 4 red blood cell [RBC] units) was performed. Blood was drawn in the emergency department, after administration of 4, 8 and 12 RBC units and 24 h post-injury. The response of ROTEM to plasma, platelets (PLTs), tranexamic acid (TXA) and fibrinogen products was evaluated in the whole cohort as well as in the subgroup of patients with ROTEM values indicative of TIC. Results Three hundred and nine bleeding and shocked patients were included. A mean dose of 3.8 g of fibrinogen increased FIBTEM CA5 by 5.2 mm (IQR: 4.1-6.3 mm). TXA administration decreased lysis by 5.4% (4.3-6.5%). PLT transfusion prevented further derangement of parameters of clot formation. The effect of PLTs on EXTEM ca5 values was more pronounced in patients with a ROTEM value indicative of TIC than in the whole cohort. Plasma transfusion decreased EXTEM clotting time by 3.1 s (- 10 s to 3.9 s) in the whole cohort and by 10.6 s (- 45 s to 24 s) in the subgroup of patients with a ROTEM value indicative of TIC. Conclusion The effects of therapy on ROTEM values were small, but prevented further derangement of test results. In patients with ROTEM values indicative of TIC, the efficacy of PLTs and plasma in correcting deranged ROTEM parameters is possibly more robust.
Identifiants
pubmed: 30609290
doi: 10.1111/jth.14378
pmc: PMC6850475
pii: S1538-7836(22)02827-6
doi:
Substances chimiques
Antifibrinolytic Agents
0
Tranexamic Acid
6T84R30KC1
Fibrinogen
9001-32-5
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-448Informations de copyright
© 2019 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Références
J Trauma Acute Care Surg. 2017 Jun;82(6S Suppl 1):S33-S40
pubmed: 28333829
Scand J Trauma Resusc Emerg Med. 2012 Feb 24;20:15
pubmed: 22364525
J Surg Res. 2018 Aug;228:154-159
pubmed: 29907206
Curr Opin Anaesthesiol. 2017 Apr;30(2):257-264
pubmed: 28085709
Ann Surg. 2012 Sep;256(3):476-86
pubmed: 22868371
J Thromb Haemost. 2019 Mar;17(3):441-448
pubmed: 30609290
Injury. 2013 May;44(5):593-9
pubmed: 22487164
Arch Surg. 2005 May;140(5):432-8; discussion 438-40
pubmed: 15897438
Trials. 2017 Oct 18;18(1):486
pubmed: 29047413
Curr Hematol Rep. 2004 Sep;3(5):324-30
pubmed: 15341698
Crit Care. 2014 Mar 26;18(2):R52
pubmed: 24666991
J Emerg Trauma Shock. 2015 Oct-Dec;8(4):199-204
pubmed: 26604525
J Trauma. 2003 Jul;55(1):39-44
pubmed: 12855879
Intensive Care Med. 2015 Feb;41(2):239-47
pubmed: 25447807
J Trauma. 2009 Aug;67(2):266-75; discussion 275-6
pubmed: 19667878
Scand J Trauma Resusc Emerg Med. 2015 Oct 01;23:74
pubmed: 26428070
J Trauma Acute Care Surg. 2014 Mar;76(3):561-7; discussion 567-8
pubmed: 24553520
Curr Opin Crit Care. 2016 Dec;22(6):591-597
pubmed: 27811561
Transfusion. 2013 Apr;53(4):783-9
pubmed: 22882316
JAMA. 2015 Feb 3;313(5):471-82
pubmed: 25647203
Ann Surg. 2019 Dec;270(6):1178-1185
pubmed: 29794847
J Thromb Haemost. 2007 Feb;5(2):289-95
pubmed: 17109736
JAMA Surg. 2013 Feb;148(2):127-36
pubmed: 23560283
Arch Surg. 2010 Oct;145(10):973-7
pubmed: 20956766
J Thromb Haemost. 2012 Jul;10(7):1342-51
pubmed: 22519961
Arch Surg. 1997 Jun;132(6):620-4; discussion 624-5
pubmed: 9197854
Br J Surg. 2017 Feb;104(3):222-229
pubmed: 28079258
J Am Coll Surg. 2013 Feb;216(2):290-7
pubmed: 23211116
J Trauma. 2003 Jun;54(6):1127-30
pubmed: 12813333
Arch Surg. 1994 Jan;129(1):39-45
pubmed: 8279939
Crit Care Med. 2011 Dec;39(12):2652-8
pubmed: 21765358
J Emerg Trauma Shock. 2012 Apr;5(2):120-5
pubmed: 22787340
Ann Surg. 2016 Jun;263(6):1051-9
pubmed: 26720428
Blood Transfus. 2012 Jul;10(3):290-5
pubmed: 22395349